alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › multicenter

multicenter

6 studies tagged multicenter, dated 2009-03-01 to 2026-08-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study 2026-08-01
  2. Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe 2026-07-09
  3. Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population 2025-06-23

Studies

6 studies carry this tag.

Date range

2009 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Alzheimer's research & therapy 1
  • Journal of the neurological sciences 1
  • Nature aging 1
  • Scientific reports 1

6 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    Lecanemab exhibited favorable 12-month safety, with no clear evidence of cognitive decline, and BBMs hold potential for treatment guidance.

  2. Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Scientific reports 2026-07-09 Treatments

    Before answering four binary questions, participants received brief explanatory information on expected clinical benefit, amyloid-related imaging abnormalities (ARIA), and the increased ARIA risk associated with APOE ε4 homozygosity.

  3. Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature aging 2025-06-23 Biomarkers

    Over 20% of patients with Alzheimer's disease (AD) worldwide are Chinese, although the efficacy of existing blood-based measures of AD biomarkers is largely unknown in Asian cohorts.

  4. Sex differences in the association of Alzheimer's disease biomarkers and cognition in a multicenter memory clinic study

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. Alzheimer's research & therapy 2025-02-18 Brain scans and imaging

    Women showed higher tau load and stronger association between amyloid and tau than men.

  5. The characteristics of camptocormia in patients with Parkinson's disease: A large cross-sectional multicenter study in Japan

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of the neurological sciences 2015-09-08 Biomarkers

    The goal of the present study was to clarify the clinical characteristics and laboratory results of parkinsonian symptoms among patients with and without camptocormia.

  6. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. The journal of nutrition, health & aging 2009-03-01 Biomarkers

    A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.

All topic tags with their study counts